Pharma funds
Executive Summary
Drug companies and their trade groups employed 1,100 lobbyists and spent $155 million on federal lobbying efforts last year, according to the Center for Public Integrity. Topping any single company, PhRMA spent more than $18 million on lobbying last year and $104 million since 1998. Meanwhile, BIO spent $5.4 million last year and almost $35 million in the same nine-year span. Pfizer spent $12 million last year, more than any other firm. In comparison, Amgen spent over $10 million, Sanofi spent $6.7 million, and Merck spent just over $4 million...
You may also be interested in...
Common Regulatory Starting Point Means EU-UK Are On Track For Medtech MRA, Say German Firms
With Brexit less than a month old, Germany’s medtech industry has renewed its push for an MRA between the EU and UK in medtech regulation.
COVID-19 Vaccines Donated To Philippines Require Emergency Use Authorization
Days after a senior Chinese government official offered free COVID-19 vaccines to the Philippines government, the country’s medicines regulator said the donated jabs would need an emergency approval before they can be used on the public.
Purespring Therapeutics: Pioneering Gene Therapy For Kidney Disorders
Interview: recently appointed CEO Richard Francis will apply his background in big pharma and biotech to building the UK start-up Purespring Therapeutics with a focus on using gene therapy technology to target renal diseases.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: